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ABSTRACT
The thyroid hormone receptors (TRs) mediate tumor suppressive effects 
in hepatocarcinoma and breast cancer cells. Here we show that incubation of 
hepatocarcinoma SK-hep1 cells expressing TRb with the thyroid hormone T3 
induces transcription of the polycistronic message coding for microRNAs 424 and 
503. TRb binds to the promoter region of these miRNAs and T3 induces an exchange 
of corepressors and coactivators inducing histone acetylation and transcriptional 
stimulation. We have validated cell cycle components as targets of these miRNAs. 
Overexpression of miR-424 mimicked the repressive effect of T3 on cell proliferation, 
growth in suspension, migration and invasion. Knockdown of miR-424 or miR-503 
reduced the inhibitory effect of the hormone. T3 increased miR-424 and miR-503 in 
breast cancer cells expressing TRb, and this induction is also involved in the anti-
invasive effects of the hormone. Furthermore, miR-424 or miR-503 depletion enhanced 
extravasation to the lungs of hepatocarcinoma cells injected in the tail vein of mice. 
The levels of these miRNAs were reduced in xenograft tumors formed in hypothyroid 
nude mice that are more invasive. Therefore, miR-424 or miR-503 mediate anti-
proliferative and anti-invasive actions of TRb both in cultured cells and in vivo.
INTRODUCTION
The actions of the thyroid hormone triiodothyronine 
(T3) are mediated by binding to nuclear receptors (TR 
alpha and beta), which act as ligand-dependent transcription 
factors by association to thyroid hormone response elements 
(TREs) in target genes [1]. TRs play an important role in 
cell proliferation and cancer [2, 3]. In hepatocarcinoma 
cells expressing TRb, T3 reduces proliferation [4], the 
responses to the ras oncogene [5], and the expression of 
pituitary tumor-transforming 1, a critical mitotic checkpoint 
protein [6]. Thyroid hormone treatment induces regression 
of carcinogen-induced hepatic nodules, reducing the 
incidence of hepatocarcinoma and lung metastasis in 
rodents [7, 8]. Furthermore, decreased TR levels and 
somatic mutations in TR genes have been found in more 
than 70% of human hepatocarcinomas, and most of these 
mutants act as dominant-negative inhibitors of TR activity 
[9–12]. Inactivation of TRb by promoter methylation, 
mutations, altered expression and anomalous subcellular 
localization of TRs has also been described in breast tumors 
[13–15]. These observations suggests that native TRs could 
act as tumor suppressors, and indeed expression of TRb 
in hepatocarcinoma and breast cancer cells retards tumor 
growth and strongly reduces invasion, extravasation and 
metastasis formation in nude mice [16, 17]
MicroRNAs (miRNAs) are single-stranded 
RNA molecules of 20–23 nucleotides length that 
post-transcriptionally control gene expression [18]. 
miRNAs bind to 3’ untranslated regions (3’ UTRs) of 
mRNA transcripts and promote mRNA degradation or 
translational inhibition [19–22]. Many miRNAs have 
oncogenic or tumor suppressive actions [23–25]. Among 
them, the miR-16 family regulates cell proliferation 
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[26–28] and miR-503, a miR-16 family member, might 
be a master regulator of the cell cycle [29]. miR-503 is an 
intragenic miRNA clustered with miR-424, other miR-16 
family member, and both are produced as a polycistronic 
message [30]. Various targets of these miRNAs regulate 
cell division, the cell cycle, mitosis or angiogenesis 
[31–37]. In addition, miR-424 and miR-503 are involved 
in cancer cell migration and invasion [38, 39], and are 
reduced in human hepatocarcinoma tumors [40].
In this work we show that miR-424 and miR-503 are 
transcriptionally induced by T3 in hepatocarcinoma and 
breast cancer cells expressing TRb, and demonstrate that 
this induction appears to play an important role in the anti-
proliferative and anti-invasive actions of the hormone both 
in cultured cells and in vivo.
RESULTS
T3 induces transcriptional activation of miR-424 
and miR-503
In miRNA microarrays we found that miR-424 
and miR-503 levels were higher (2.32- and 2.99-fold, 
respectively) in T3-treated SK-hep1 cells expressing TRb 
(SK- TRb) than in untreated cells. The expression levels 
of both miRNAs measured by quantitative RT-PCR were 
increased upon T3 treatment, validating the microarrays 
results (Figure 1A). This increase was not found in 
parental cells that do not express TRb (Suppl. Figure 1), 
indicating that the effect of T3 requires binding to the 
receptor. Expression of miR-424 and miR-503 was, 
however, undetectable in parental and TRb-expressing 
HepG2 cells both in the absence and presence of T3 
(Suppl. Figure 2A,B). In addition, T3 did not increase 
the levels of these miRNAs in non-transformed THLE-2 
hepatocytes. However, the hormone induced miRNA 
expression in HH4 hepatocytes, and this induction 
was stronger after transduction with a retroviral vector 
encoding TRb (HH4-TRb cells) (Suppl. Figure 2B). 
These cells express the receptor at similar levels as those 
found in SK-TRb or HepG2-TRb cells (Suppl. Figure 2B). 
Therefore, induction of miR-424 and miR-503 by T3 is 
not restricted to hepatocarcinoma cells.
T3 increased the levels of pri-miRNA-424 and pri-
miRNA-503 in SK- TRb cells (Figure 1B), suggesting 
that the hormone induces transcription of the miRNAs 
precursor. To analyze the presence DNA elements that 
could mediate T3-dependent transcription, we constructed 
luciferase reporter plasmids containing different fragments 
of the miRNAs 5´-flanking region (Figure 1C). Activity 
of the –923/-34 region with respect to the transcription 
start site of miR-424 was increased by T3. However, no 
change was observed when cells were transfected with 
the luciferase plasmid alone or with other fragments, 
indicating that this region contains the elements 
responsible for stimulation of miR-424/503 by T3.
ChIP assays were carried out with the region 
containing the putative response elements (Figure 1D). 
TRb bound constitutively to two overlapping fragments 
of the proximal promoter region, whereas no receptor 
recruitment to an irrelevant upstream region (-3723-/3911) 
was observed (Figure 1E). Furthermore, T3 caused 
dissociation of the corepressor NCoR and recruitment of 
p160 coactivators and CBP to the promoter. Consequently, 
enrichment on acetylated H4 histone was also detected 
(Figure 1F).
(Continued)
Figure 1: T3 induces transcription of miR424 and miR503 in hepatocarcinoma cells. (A) miR-424 and -503 levels after 48 h 
of treatment with 5nM T3 in TRb-expressing SK-hep1 cells. Fold change of these microRNAs are expressed relative to control untreated 
cells. (B) pri-miRNA levels measured under the same conditions.
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Figure 1: (C) Schematic diagram of the 5´-flanking region of miRNA424/503, and the fragments used in transient transfection studies. 
Cells were transfected with the empty luciferase plasmid or with the plasmids containing the indicated regions of the miRNA-424/-503 
promoter. Luciferase activity was determined in control cells and in cells treated with T3 for 48 h. (D) Schematic representation of the 
miRNA-424/-503 proximal promoter depicting the position of the putative receptor binding sites (black boxes) and the primers used in 
chromatin immunoprecipitation (ChIP) assays (arrows). (E) ChIP assays with IgG and TRb antibodies and the indicated fragments of the 
miRNA-424/-503 promoter. (F) Binding of TRB, the corepressor NCoR, the coactivators CBP, SRC-1 and p/CIP and acetylated histone H4 
to the miRNA-424/-503 promoter region -244/-84, determined by ChIP assays after 1 h of incubation with T3.
T3 down-regulates miR-424 and miR-505 targets
miR-424 and miR-503 are predicted to target many 
mRNAs (microRNA and TargetScan), some of them 
already validated [31, 37, 41]. In SK-TRb cells, T3 down-
regulated mRNA levels of Ccnd2, Cdk6, Cdc25, E2f3, 
c-Myb, Wee1 and Chk1 involved in cell proliferation 
and cancer (Figure 2A). Furthermore, the levels of these 
proteins, assessed by western blot, were reduced in 
T3-treated cells (Figure 2B). This is compatible with the 
hormone-dependent induction of miRNAs 424 and 503.
The 3´-UTRs of the tested mRNAs have sequences 
that could anneal to the seed sequences of miR-424 and 
503 (Suppl. Figure 3). To validate the predicted miRNA/
mRNA interactions, we used luciferase vectors containing 
the 3´-UTR of c-Myb, Cdc25A, Wee1 and Chk1. T3 
did not affect the activity of the plasmid without UTR 
sequences, but significantly inhibited the activity of 
the UTR-containing constructs (Figure 2C). Therefore, 
T3 appears to represses target mRNA stability as a 
consequence of the increased levels of miR-424/503.
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Figure 2: T3 down-regulates expression of miRNA424/503 targets. (A) mRNA levels for the indicated putative targets of 
miRNAs 424 and 503 were measured by quantitative PCR in SK-TRb cells treated without and with T3 for 48 h. Fold change of these 
mRNAs, normalized to RPL19 mRNA, are expressed relative to the values obtained in control untreated cells. (B) Western blot analysis 
of the same targets. Tubulin was used as a loading control. (C) Luciferase reporters fused to the c-Myb, Cdc25, Wee1 and Chek1 3,-UTRs, 
as well as an empty plasmid, were transfected into SK-TRb cells. A mutant construct of the proximal binding site in the Cdc25 3´-UTR is 
designated Mut1, the mutation in the distal binding site Mut2, and the mutation of both binding sites Mut 1+2. Mut3 indicates mutation of 
the distal binding site in the c-Myb-3´-UTR, Mut4 of the proximal site and Mut 3+4 of both sites. Luciferase activity was measured after 
36h incubation in the presence and absence of T3.
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Previously described mutants of the putative miR-
424/503 binding sites in the Cdc25 and c-Myb UTRs were 
used to analyze induction by T3. Cdc25 3´-UTR contains 
two binding sites for these miRNAs [41]. Mutation of the 
first site did not affect inhibition by T3. However, mutation 
of both sequences abrogated the repression by the hormone 
(Figure 2C). This shows that the reported binding sites for 
miR-424/503 are relevant for the effect of T3. The c-Myb 
UTR also contains two putative sites for these miRNAs. 
Mutation of the distal site alone or in combination with the 
proximal site abolished responsiveness to T3 (Figure 2C), 
in agreement with the finding that this binding site 
mediates the effect of miR-424 [42].
To further test the functional relevance of miR424 
and miR-503 induction by T3, we conducted experiments 
of gain and loss of function of the miRNAs and evaluated 
the expression of the different targets by western blotting. 
Over-expression of miR-424 (Figure 3A) mimicked 
the effect of T3, decreasing their levels (Figure 3B). 
Furthermore, the reduction caused by T3 and miR-424 was 
not additive, indicating a common mechanism of action. 
On the other hand, transfection with miRNA inhibitors, 
which caused a strong reduction of miR-424 or miR-503 
levels (Figure 3C), reversed the inhibitory effect of T3 on 
CHK1, WEE1, CDC25, c-MYB or E2EF, while CDK6 or 
CCND2 levels remained low (Figure 3D).
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Figure 3: Influence of miR-424 expression and miR-424 and miR-503 depletion on the effect of T3 on target proteins. 
(A) miR-424 levels in untreated and T3-treated cells transfected 36 h before with an expression vector for miR-424 (pSGU-miR424) or 
the corresponding empty vector. (B) The levels of CHK1, WEE1, CDC25, E2F3, c-MYB, CDK6 and CCND2 were measured by western 
blot. ERK2 levels were used as a loading control. (C) SK-TRb cells were transfected with anti-miRNAs for miR-424 or miR-503, or with 
a negative control, and the levels of the corresponding miRNAs were determined in untreated and T3-treated cells 36 h after transfection. 
(D) Levels of the indicated proteins were analyzed by western blot under the same conditions.
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miR424/503 depletion antagonizes the anti-
proliferative and anti-invasive actions of T3
Since miR-424 and miR-503 down-regulate 
proteins with an important role in cell proliferation, we 
analyzed their effect on the cell cycle of SK-TRb cells. 
Transfection of miR-424 increased the percentage of 
cells arrested in G1, causing a concomitant reduction 
in the number of cells in S-phase and a small increase 
of sub-G1 cells. Incubation with T3 did not induce cell 
death, but caused G1 increase and reduction of S-phase, 
although less marked than that caused by miR-424 
overexpression. In addition, the hormone had little effect 
in cells overexpressing the miRNA (Figure 4A). Depletion 
of miR-424 or miR-503 strongly inhibited the effects of 
T3, and combined knockdown of both miRNAs abolished 
T3-dependent increase in G1 and reduction of S-phase. 
This indicates the crucial role of miR-424/503 induction 
for this hormonal effect (Figure 4B).
TRb expression prevents the ability of SK-hep1 
cells to grow in the absence of a solid substrate [17]. 
Therefore, we next examined the effect of miR-424 and 
miR-503 on growth of SK-TRb cells in suspension under 
rocking conditions. miR-424 overexpression mimicked 
the effect of T3 inhibiting growth in suspension, while 
depletion of either miR-424 or miR-503 reversed T3-
dependent inhibition (Figure 4C). Thus, miR-424 and 
miR-503 induction is also involved in this action of T3 
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Figure 4: Inhibition of miR-424 and -503 reverses the effect of T3 on SK-TRb cell proliferation. (A) Cell cycle analysis in 
cells transfected with pSGU-miR424 or an empty vector. DNA contents were measured after 48 h of treatment with and without T3. The 
results are shown as the % of cells in sub-G1, G1, S and G2/M phases. (B) Changes in the cell cycle after transfection with the negative 
control RNA, anti miR-424, anti miR-503 or both. The percentage of change in T3 versus untreated cells for each condition was plotted. 
(C) Cells were transfected with the indicated anti-miRNAs and after 24h were detached from the plates and grown under rocking conditions 
during an additional 24 h period in the presence or absence of T3. Cells were then plated and MTT was assayed. Results were expressed 
relative to MTT values obtained in cells inoculated in parallel without agitation. (D) MTT values in cells treated with or without T3 for 72 
h and with the indicated concentrations of cisplatin for an additional 48 h period.
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in SK-TRb cells. Transfection of miR-424 also reduced 
growth in suspension of HepG2-TRb cells that do not 
express miR-424 or miR-503 (Suppl. Figure 4A). In 
contrast, in these cells T3 did not reduce growth and, as 
expected, the miRNA inhibitors were ineffective (Suppl. 
Figure 4B).
Increased expression of Wee1 and Chk1 secondary 
to reduced miR-424 and other family members has been 
associated with resistance to cisplatin [36]. In agreement 
with this finding, T3 caused a moderate but statistically 
significant reduction of SK-TRb cell survival in response 
to the drug, with the EC50 decreasing from 1.6 µg/ml to 
0.8 µg/ml (Figure 4D).
We next studied whether T3-induced miRNA 
increase could also affect cellular migration. T3 treatment 
or transfection with pSGU-miR424 retarded SK-TRb cell 
migration in wound assays (Figure 5A). Conversely, miR-
424 or miR-503 depletion increased wound closure and, 
when used in combination, reversed the inhibitory effect 
of T3 (Figure 5B). Therefore, induction of miRNAs 424 
and 503 appears to mediate the inhibitory effect of T3 on 
hepatocarcinoma cell migration.
Figure 5: miR-424 and -503 are involved in the inhibitory effect of T3 on hepatocarcinoma cell migration. (A) Cells 
transfected with pSGU-miR424 or the empty vector were treated with mitomycin C to block proliferation and wound healing was followed 
for 3 days in the presence and absence of T3. Photographs were taken at time 0 and at day 3. Representative images are shown. (B) Similar 
experiment performed in cells transfected with a control anti-miRNA, or anti-miR-424 and anti-miR-503 alone or in combination.
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Our next objective was to investigate the possible 
role of these miRNAs on the reduced invasive capacity 
shown by T3-treated SK-TRb cells [17]. Figure 6A shows 
that over-expression of miR-424 again mimicked the 
effect of T3, reducing cellular invasion through matrigel. 
Furthermore, depletion of miR-424, miR-503, or both, 
increased cellular invasion and reduced noticeably the 
inhibitory effect of T3. Therefore, induction of these 
miRNAs by T3 also appears to play a role on the anti-
invasive actions of the hormone (Figure 6B).
miR424/503 depletion increases extravasation of 
hepatocarcinoma cells
TRb can limit cancer cell extravasation in vivo [17]. 
Therefore we next determined if miR-424 and miR-503 
could also regulate this process. To analyze this, SK- TRb 
cells transfected with a negative control of with anti-miRs 
were injected into the tail of nude mice. As illustrated in 
Figure 7, miRNA depletion increased very significantly the 
amount of cells present in the lungs of the mice. Therefore, 
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Figure 6: Depletion of miR-424 and miR-503 reduces the inhibitory effect of T3 on cellular invasion. (A) SK-TRb 
cells were transfected with pSGU-miR424 or the empty vector and incubated for 48 h in the presence and absence of T3. Cells were 
then inoculated into the upper chamber of Transwell plates containing matrigel and treated with or without T3. Sixteen hours later cells 
that passed through the filter were stained and scored. Representative images are shown at the left and quantifications at the right panel 
(B) Similar experiment in cells transfected with a negative control anti-miRNA, anti-miR-424, anti-miR-503 or both.
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the induction of miRNAs 424 and 503 by endogenous 
thyroid hormones could inhibit cell extravasation in vivo.
T3 increases miR424 and 503 levels in breast 
cancer cells
To analyze if induction of the miRNAs by T3 could 
also occur in other types of tumor cells, we measured the 
levels of miRNAs 424 and 503 in TRb-expressing MDA-
MB-468 breast cancer cells (MDA-TRb) cells (Figure 8A). 
T3 increased the levels of both miRNAs (Figure 8B), and 
in agreement with this induction reduced the levels of their 
putative target proteins (Figure 8C). The functional role of 
miR-424 and miR-503 induction by T3 in MDA-TRb cells 
was also examined. Growth in suspension was abolished 
by T3 and was restored after depletion of miR-424, miR-
503, or both (Figure 8D). The hormone also decreased 
MDA-TRb cells invasion through matrigel and expression 
of miR-424 had a similar effect (Figure 8E). In addition, 
miR-424 and/or miR-503 depletion increased cellular 
invasion and reduced the inhibition by T3 (Figure 8F). 
Therefore, induction of miRNAs 424 and 503 by T3 is 
also functionally relevant in breast cancer cells.
Hypothyroidism reduces miR-424 and miR-503 
levels in xenografts
We have previously shown that when SK-TRb or 
MDA-TRb cells were inoculated into hypothyroid nude 
mice, tumors were more invasive and metastatic growth 
was enhanced [16]. To analyze whether thyroidal status 
could also alter miRNA expression in the tumors, we next 
compared miR-424 and miR-503 levels in xenografts 
formed by inoculation of SK-TRb and MDA-TRb cells 
into euthyroid and hypothyroid mice. As shown in 
Figure 9, miR-424 and miR-503 expression was reduced 
in the tumors developed in hypothyroid mice, correlating 
with their increased invasive properties. Thus, the thyroid 
hormones can regulate expression of these miRNAs in 
vivo in hepatocarcinoma and breast cancer cells.
DISCUSSION
In the present study, we have investigated the 
function of miR-424 and miR-503 in the response of 
hepatocarcinoma to T3. The hormone increased the levels 
of these miRNAs in SK-TRb cells and this induction 
plays an important role in the anti-tumorigenic and anti-
invasive actions mediated by binding of T3 to the receptor. 
Induction of these miRNAs by T3 was also found in non-
transformed hepatocytes and in MDA- TRb breast cancer 
cells, indicating that the phenomenon is not specific for the 
hepatocarcinoma cell line.
T3 increased the level of both pri-miRNAs and 
stimulated the activity of the proximal promoter of miR-
424/miR-503 in SK-TRb cells, indicating that the hormone 
induces transcription of the polycistronic message that 
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Figure 7: Depletion of miRNAs 424 and 503 enhances extravasation in vivo. SK-TRb cells transfected with a negative control 
or with the indicated anti-miRNAs were injected into the tail vein of nude mice. The presence of human Alu sequences in the lungs was 
determined by quantitative PCR at 9 h after injection. Data are expressed as the percentage of the inoculated DNA with respect to the total 
DNA injected.
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encodes both miRNAs. T3-dependent transcriptional 
stimulation of target genes involves binding of the TR 
to TREs, inducing the release of corepressors and the 
recruitment of co-activators that lead to local alteration of 
chromatin structure [1]. ChIP analysis confirmed that TRb 
binds to the miR-424/503 promoter, and that T3 releases 
the corepressor NCoR and recruits p160 coactivators such 
as SRC-1 or p/CIP with histone acetyltransferase (HAT) 
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Figure 8: T3 induces expression of miR424 and miR503 in breast cancer cells. (A) Western blot analysis of TRb in parental 
MDA-MB-468 (MDA), TRb-expressing MDA (MDA-TRb) cells and SK-TRb cells. ERK2 was used as a loading control. (B) miR-424 
and -503 levels in MDA-TRb cells after 48 h of treatment with 5nM T3. Fold change of these microRNAs are expressed relative to 
control untreated cells. (C) Western blot analysis of the putative miR424/503 targets CDC25, CDK6, CHK1, WEE1, c-MYB, and E2F3 in 
untreated and T3-treated MDA-TRb cells. ERK2 was used as a loading control. (D) Growth in suspension under rocking conditions was 
analyzed in MDA-TRb cells previously transfected with the indicated anti-miRNAs. MTT was assayed after 24 h growth in the presence 
and absence of T3. Results were expressed relative to MTT values obtained in cells inoculated in parallel without agitation. (E) Invasion 
through matrigel was measured in MDA-TRb cells previously transfected with pSGU-miR424 or the empty vector and incubated for 48 h 
with and without T3. Invasion was then performed for 16 h in the presence and absence of the hormone and the cells that passed through 
the filter were counted (F) Similar experiment in cells transfected with a negative control anti-miRNA, anti-miR-424, anti-miR-503 or both. 
The results are expressed relative to the number of cells obtained in the control untreated cells.
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activity. p160 coactivators act as primary coactivators 
interacting with TRs, but they also recruit secondary 
coactivators such as the HAT CBP/p300 [43]. We 
observed hormone-dependent recruitment of CBP to the 
miR-424/503 promoter. Histone acetylation is a critical 
step in nuclear receptor-mediated hormone signaling and 
histone acetylation of the miR-424/503 promoter was also 
induced upon T3 treatment.
miR-424 and 503 play an important role in 
tumorigenesis. They are down-regulated in several tumors, 
suggesting that these miRNAs have tumor suppressive 
activity [37, 39, 42, 44, 45], although miR-424 is 
upregulated in some tumors [46]. The anti-tumorigenic 
actions of miR-424 and miR-503 could be related to their 
effect on the cell cycle. Indeed, elevated levels of both 
promote cell quiescence and differentiation, which is 
consistent with the role of this family in targeting multiple 
genes involved in the G1-S transition [27–29, 33, 41]. Our 
results show that T3 reduces expression of several cell 
cycle genes in hepatocarcinoma cells including Ccnd2, 
Cdk6 and Cdc25 that control entry into and progression 
through various phases of the cell cycle; the Wee1 kinase, 
a key regulator during S phase, preventing entry into 
mitosis until DNA replication has been completed [47]; 
the checkpoint gene Chk1 [48]; the transcription factor 
E2f3, a member of the E2f family that regulates expression 
of genes required for DNA synthesis at the G1/S phase 
boundary [49]; or the c-Myb proto-oncogene also involved 
in cell proliferation and cancer [50]. Interestingly, 
expression of the target proteins of miR-424 and miR-503 
was also decreased in T3-treated breast cancer cells.
The increased transcription of miR-424 and miR-
503 is relevant for the regulation of most of these proteins 
by the hormone. On one hand, T3 suppressed stability of 
target mRNAs in experiments with the 3´-UTRs, which 
contain binding sites for miR-424/503, and on the other 
hand, gain- and loss-of-function experiments revealed 
that these miRNAs mediate T3-dependent changes in 
the levels of the target proteins. Furthermore, T3 arrested 
hepatocarcinoma cells in G1 and the knockdown of miR-
424 and miR-503 reversed this effect, underscoring the 
important role of these miRNAs in the inhibition of cell 
proliferation.
A decrease in the expression of the miR-16 family 
mediates resistance to cisplatin in cancer cells as a 
consequence of the increased levels of Wee1 and Chk1 
[36]. Our results indicate that T3 significantly repressed 
Wee1 and Chk1 3´-UTR activity and reduced the levels of 
these proteins. This led us to the hypothesis that elevated 
expression of miR-424 and 503 in response to T3 could 
sensitize cancer cells to chemotherapy. In agreement with 
this idea, we found that hepatocarcinoma cell survival in 
response to cisplatin was moderately reduced after T3 
treatment, suggesting a novel anti-tumorigenic mechanism 
Figure 9: Reduced miR-424 and miR-503 expression in tumor xenografts developed in hypothyroid mice. Euthyroid and 
hypothyroid nude mice were injected with SK-TRb (A) and MDA-TRb cells (B), and the levels of miR-424 and miR-503 were determined 
8 weeks later in the tumors. Representative Masson´s trichrome staining of tumors formed in euthyroid and hypothyroid mice are illustrated 
in the bottom panels.
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for this hormone. Down-regulation of Chk1 could also 
play a role in the anti-tumorigenic effects of TRb, since 
suppressed miR-424 expression via up-regulation of Chk1 
contributes to the progression of cervical cancer [37].
Our results show that miR-424 and 503 affected 
hepatocarcinoma and breast cancer cell invasion in 
vitro. This is consistent with the previous report that 
miR-503 was down-regulated in the highly metastatic 
hepatocarcinoma cell line HCCLM3 when compared with 
MHCC97-L cells with a lower metastatic potential [39]. 
The invasive capacity of T3-treated cells was significantly 
recovered after depletion of miR-424 and 503, indicating 
that induction of these miRNAs participates in T3-
dependent inhibition of SK-TRb and MDA-TRb cell 
invasion.
The in vivo relevance of thyroid hormone regulation 
of miR-424 and 503 was demonstrated by the finding 
that tumor xenografts formed by SK-TRb and MDA-
TRb cells in hypothyroid mice expressed lower levels 
of these miRNAs than those developed in animals with 
normal thyroid function. Interestingly, correlating with the 
lower levels of miR-424 and 503 the tumors formed in 
the hypothyroid hosts had a more mesenchymal phenotype 
and were more invasive [17].
TRb-expressing hepatocarcinoma cells have a 
reduced capacity of extravasation to the lungs when they 
are injected into the tail vein of nude mice. Therefore, 
the receptor appears to have anti-metastatic activity 
by blocking not only the ability of cancer cells to 
proliferate and colonize the lung parenchyma, but also 
by limiting cancer cell extravasation [17]. Here we show 
that extravasation of hepatocarcinoma cells in vivo was 
strongly enhanced when miRNAs 424 and 503 were 
depleted. Therefore, induction of these miRNAs could play 
an important role in the inhibitory action of the receptor. 
Additionally, miR-424 and miR-503 depletion restored the 
ability of T3-treated hepatocarcinoma and breast cancer 
cells to growth in suspension under rocking conditions. 
The competence to grow under these circumstances should 
enhance survival of cells in the circulation and therefore 
increase their ability to metastatize.
Taken together our results show that binding of 
T3 to the TRb receptor induces transcription of miR-
424 and miR-503. This induction is relevant to explain 
the tumor suppressive actions of this nuclear receptor. 
The thyroid hormone-dependent increase of miR-424 
and miR-503 appears to modulate tumor growth and 
progression in multiple ways. Besides affecting tumor cell 
proliferation and increasing sensitivity to DNA damaging 
agents, elevated levels of miR-424 and miR-503 are 
required for the inhibitory effect of the hormone on cell 
migration and invasion. As suggested by our results, 
the increased miRNA expression could reduce tumor 
invasion, intravasation, survival of the cancer cells in the 
bloodstream, and the extravasation and colonization of 
the metastatized target tissue. There are many predicted 
targets of miR-424/503 and future studies are necessary 
to identify the genes responsible for the inhibition of cell 
migration and invasion by these miRNAs that could affect 
tumor progression in vivo.
In summary, our findings suggest that increased 
transcription of miRNAs 424 and 503 secondary to thyroid 
hormone binding to its receptor plays a relevant role in 
the anti-proliferative and anti-invasive actions of this 
nuclear receptor in tumor cells. These miRNAs appear 
to have tumor suppressive actions and could be potential 
therapeutic targets.
MATERIALS AND METHODS
Cells
Human hepatocarcinoma SK-TRb cells and MDA-
TRb cells, stably expressing the beta 1 isoform of the 
thyroid hormone receptor were derived from SK-hep1 
and MDA-MB-468 cells, respectively, as previously 
described [17]. Hep-G2 cells expressing TRb were a 
kind gift of M. Privalsky. Parental and TRb cells were 
maintained in Dulbecco's modified Eagle's media 
(DMEM) supplemented with 10% fetal bovine serum 
(FBS) depleted of thyroid hormones by treatment with 
resin AG-1-X8 (Bio-Rad). The human hepatocyte cell line 
HH4, a gift of J. Campbell and I. Fabregat, was cultured 
in collagen-coated plates with William’s E medium 
containing 15% fetal calf serum. The cell line THLE-2 
derived from primary normal liver cells, a gift of P. Martín, 
was cultured in Airway Epithelial cell Media (PromoCell 
ref-21160). When indicated, cells were incubated in serum 
free medium.
Retroviral infection
HEK293T cells were cotransfected with 10 µg of 
pLPCX or pLPCX-TRb that encodes the human TRb 
isoform, 3.5 µg of VSV, and 6.5 µg of gag-pol constructs 
(a gift from Dr. P.M. Comoglio) using calcium phosphate. 
Viral supernatants were harvested 24 and 48 h post-
transfection, filtered, and used for infections of HH4 
cells in the presence of 4 µg/ml of polybrene. Cells were 
selected with 2µg/ml puromycin. Pools of resistant cells 
(HH4-TRb cells) were cultured with thyroid hormone-
depleted FBS.
Plasmids
Fragments +28953/+29193 and +13948/+14644 
of the 3'-UTR of the CHEK1 and WEE1 mRNAs 
with predicted miR-424/503 target binding sequences 
were amplified by PCR using the primers listed under 
Supplementary material. These fragments were cloned 
downstream of the luciferase coding region in pGL3 
vector. Reporter plasmids containing the wild-type and 
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mutant 3'-UTRs of Cdc25 and c-Myb were a king gift of 
A. Dutta and F. Grässer and were described previously 
[41, 42]. The expression vector for miR-424 (pSGU-
miR424) and the corresponding empty vector were a 
kind gift from I.V. Ramakrishnan [34]. Fragments of the 
5´-flanking region of miR424/503 were obtained by PCR 
and were cloned in pGL3 with the primers listed under 
Supplementary materials.
Transfection and reporter assays
Cells, grown in 24 wells plates, were transiently 
transfected with 300 ng of reporter plasmids and 30 ng 
of pRL-TK-Renilla (Promega) as a normalizer control, 
using TransFectin™ (BioRad). When appropriate, the 
reporter was cotransfected with an expression vector 
for miR-424 (pSGU-miR424, 200 ng) or with the same 
amount of an empty vector. Anti-miR Inhibitor for miR-
424, miR-503 and the Anti-miR Negative Control#1 were 
purchased from Ambion (Cat. AM10306 and AM10378). 
Transfection of miRNA inhibitors was performed using 
60 nM of each Anti-miR and TransFectin™ (BioRad) as 
recommended by the manufacturer. Each experiment was 
performed in triplicate and was repeated at least 3 times. 
Data are mean ± S.D and are expressed as fold induction 
over the values obtained in the control cells.
Quantitative real time RT-PCR analysis of miRNAs, 
pri-miRNAs and mRNAs
miR-424 and miR-503 were quantified by the stem-
loop real-time PCR, with primers purchased from Applied 
Biosystems. RNU48 RNA was used as an internal control. 
Pri-miRNA levels were analyzed by quantitative real-time 
PCR using specific primers from TaqMan Pri-miRNA 
Assays (Applied Biosystems). PCRs reactions were 
detected with FastStartUniversal Sybr Green (Roche). 
Data analysis was done using the comparative CT method 
and data were corrected with the RPL19 mRNA levels. 
Primers used are indicated in the Supplementary material.
Western blotting
Proteins from cell lysates (20–40 µg) were separated 
in SDS-PAGE and transferred to PDVF membranes 
(Immobilon Millipore) that were blocked with 4% BSA. 
Incubation with primary antibodies was performed 
overnight at 4ºC and with the secondary antibody for 1 h 
at room temperature. Primary antibodies and the dilution 
used are listed in the Supplementary material.
Chromatin immunoprecipitation assays
Cells were plated in 150mm dishes and treated with 
5nM T3 for 1h, fixed, lysed following specifications of 17–
295 Upstate kit, and sonicated in a Bioruptor UCD-200TM 
(Diagenode, Belgium). In each immunoprecipitation 
4x106 cells and the antibodies listed in the Supplementary 
material were used. DNA was purified, precipitated and 
the fragments of miR424/503 promoter amplified with the 
primers listed under Supplementary material.
Growth in suspension
Cells were inoculated in the presence or absence of 
5nM T3 and kept under agitation under rocking conditions 
for 24 h. Cells were then plated in 24-wells plates and after 
4 h were used for MTT assays. Results were expressed 
relative to MTT values obtained in cells inoculated in 
parallel without agitation.
Flow Cytometry
Floating and adherent cells from triplicate cultures 
were collected, washed, fixed and centrifuged. Pellets were 
stained with propidium iodide and sorted in FACScan 
Q4 (Becton Dickinson, Mountain View, CA) cell sorter. 
Percentages of cells in sub-G1, G1, S, and G2-M phases 
were calculated with Mod Fit software for Windows.
Migration assays
For migration assays, cells were plated in wells 
containing Culture-Inserts (Ibidi). Twenty-four hours later 
cells were treated for 2 h with 10µg/ml mitomycin C and 
inserts were removed. Wound healing was followed for 
3 days and photographs were taken at the beginning of the 
assay (t=0 h) and at day 3 at magnification ×100.
Invasion assays
Cells were inoculated in Transwell plates containing 
matrigel. Conditioned medium obtained from NIH3T3 
cells incubated for 48 h in serum-free-medium and 0.1% 
bovine serum abumin (BSA) was placed in the outer 
chamber. Medium containing 0.1% BSA was used as a 
negative control. Invasion lasted for 16 h, and occurred in 
the presence and absence of hormone. Filters were fixed 
with methanol and cells were stained with crystal violet, 
sealed with Mowiol and scored.
Xenografts
Groups of athymic nude mice (athymic nude-Nu) 
8–10 weeks old were used for xenografting studies. 
SK-TRb cells (1×106 cells in 100 µl PBS) were injected 
subcutaneously into each flank, and MDA-TRb cells were 
orthotopically inoculated into the fat pad of the second 
abdominal right mammary gland. Cells were implanted in 
euthyroid mice and in mice made hypothyroid by treatment 
with 0.02% methymazole and 0.1% potassium perchlorate 
in the drinking water as described previously [16]. 
Experiments were carried out following the regulations 
of the CSIC for animal care and handling (RD 53/2013). 
Tumors were fixed in 4% buffered formalin and embedded 
in paraffin wax, and sections (4–5 µm) were stained with 
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Masson´s Trichrome. miR-424 and miR-503 levels were 
analyzed in the tumors 8 weeks after inoculation.
Extravasation assays in nude mice
Groups of 6 immunodeficient nude mice were 
injected into the tail vein with 4x106 SK-TRb cells 
suspended in 100 µl of PBS. Animals were sacrificed 
and exsanguinated by intra-cardiac puncture at 9 h 
after injection. Lungs were excised and placed in vials 
containing 1xPBS. PBS was changed daily for 3 days to 
eliminate non-incorporated cells. Lungs were divided into 
3 pieces (upper, medium and lower) and genomic DNA 
was extracted from the different segments. Colonization 
of the organ by the hepatocarcinoma cells was quantitated 
by real-time PCR of human APO Alu sequences located in 
human chromosome 11 [51], with the primers listed in the 
Supplementary material. Results are expressed as the % of 
amplified human DNA, with respect to the amount of total 
DNA injected. No amplification of human Alu sequences 
was found in blood, which was used as a negative control.
Statistical analysis
Data are expressed as means ± S.D. Statistical 
significance was determined by Student t-test or analysis 
of variance (ANOVA) followed by the Bonferroni test 
for experiments with more than two experimental groups. 
Significance between untreated and T3-treated cells 
is indicated in the figures as *P <0.05, **P <0.01 and 
***P <0.001. All analysis were performed using SPSS 
(Statistical Software for Social Sciences, Chicago, IL, USA).
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